VEGFR2 — Drug Target
All drugs that target VEGFR2 — marketed and clinical-stage. Includes 5 drug classes acting on this target.
Drug classes
VEGF inhibitor · tyrosine kinase inhibitor · Angiogenesis inhibitor · Angiogenesis inhibitor, Microtubule inhibitor · Tyrosine kinase inhibitor
Phase 3 pipeline (4)
- Ramucirumab DP (IMC-1121B) · Eli Lilly and Company · VEGF inhibitor · Oncology
Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. - Rivoceranib (Apatinib) · Jiangsu HengRui Medicine Co., Ltd. · tyrosine kinase inhibitor · Oncology
Rivoceranib (Apatinib) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2). - ramucirumab (IMC-1121B) · Eli Lilly and Company · Angiogenesis inhibitor · Oncology
Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. - Ramucirumab+ paclitaxel · AstraZeneca · Angiogenesis inhibitor, Microtubule inhibitor · Oncology
Ramucirumab is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, while paclitaxel is a microtubule inhibitor that blocks cell division.
Phase 2 pipeline (2)
- ApatinibMesylateTablets · Chang-Ming Huang, Prof. · Tyrosine kinase inhibitor · Oncology
Tyrosine kinase inhibitor - Apatinib Combined With Docetaxel · Jiangsu ShengDiYa Medicine Co., Ltd. · tyrosine kinase inhibitor · Oncology
Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.